18 nov: Scor 400.000 på din pension
19 nov: Den vildeste Porsche
19-11-2010 10:37:27

AstraZeneca confirms eyeing Astra Tech spin-off

Relateret indhold

LONDON (Reuters) - AstraZeneca (Astrazeneca PLC ORD SHS $0.25) confirmed on Friday it was considering spinning off its Astra Tech dental implants and medical devices business and had hired JP Morgan Chase (JP Morgan Chase & Co) to help with a strategic review of the unit.

A source familiar with the situation said earlier this week that the Anglo-Swedish drugmaker was looking to sell the non-core Swedish-based business for some $2 billion (1.2 billion pounds) after hiring the bank as adviser.

"AstraZeneca continues to evaluate all alternatives for value maximisation from this business and any final decision will only be made when the results of the review have concluded," the company said in a brief statement.

A company spokeswoman confirmed that a sale of the operation was one option. She declined to comment on the timing of any decision.

The expected sale of Astra Tech highlights AstraZeneca's current focus on boosting returns as the group heads into a wave of patent expiries on some of its biggest-selling medicines.

In contrast to some of its rivals -- such as GlaxoSmithKline (Glaxosmithkline PLC ORD 25P), Novartis and Sanofi-Aventis -- AstraZeneca has stayed focussed on its core pharmaceuticals business rather than seeking diversification.

Shares in the company were barely changed by 9:30 a.m., down 0.3 percent at 3053.5 pence, in line with a flat Stoxx 600 European healthcare sector index .

The Astra Tech business could be of interest to U.S. companies such as privately held Biomet, Medtronic (Medtronic plc Ordinary Shares), 3M (3M Company), Danaher (Danaher Corporation) and Dentsply International (Dentsply Sirona Inc), as well as private equity firms, according to industry analysts.

Companies operating in the sector in Europe include Swiss dental implant firms Nobel Biocare and Straumann .

Astra Tech, best known for dental implants, also sells urological catheters, breathing aids and blood management systems used in surgery. It has 2,200 employees worldwide and produced revenue in 2009 of $506 million, AstraZeneca said.

(Reporting by Ben Hirschler; Editing by Greg Mahlich)

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Schweizere kan skubbe DSV i forventet positiv åbning

27-02-2017 08:24:19
Et løftet kursmål til DSV er en af få nyheder af nævneværdig størrelse mandag morgen, hvor det generelle danske aktiemarked ser ud til at kunne indlede ugen med..

Rovsing mindsker driftsunderskud i første halvår og opjusterer

24-02-2017 16:36:15
Omsætningen i Rovsing, der har hovedkontor i Skovlunde ved København og blandt andet producerer testsystemer til satellitter og elektroniske produkter til rumin..

KORR. Genmab/Sydbank: Positiv anbefaling er godt nyt - og ventet

24-02-2017 14:04:12
(Korr: "uger" rettet til "måneder" i sjette afsnit)Det europæiske lægemiddelagenturs (EMA) komite for medicinske produkter for human anvendelse (CHMP) har givet..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Schweizere kan skubbe DSV i forventet positiv åbning
2
Vindmølleproducent mister en tredjedel af sin værdi på tre dage
3
GN/Goldman: Sætter tredjehøjeste kursmål
4
Genmab nominerer to nye til bestyrelsen og opfylder kvindekvote
5
Coloplast/Goldman: Kursmålet får en tak op

Relaterede aktiekurser

Glaxosmithkline PLC ORD .. 1.645,50 0,4% Stigning i aktiekurs
Astrazeneca PLC ORD SHS .. 4.623,50 0,3% Stigning i aktiekurs
Straumann N 423,50 -0,1% Fald i aktiekurs
Danaher Corporation 86,08 0,0% Aktiekurs uændret
JP Morgan Chase & Co 90,33 0,0% Aktiekurs uændret
3M Company 187,41 0,0% Aktiekurs uændret
Dentsply Sirona Inc 62,79 0,0% Aktiekurs uændret
Medtronic plc Ordinary S.. 81,03 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. februar 2017 12:16:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB2 - 2017-02-27 12:16:06 - 2017-02-27 12:16:06 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x